By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adnexus, A Bristol-Myers Squibb R&D Company 

100 Beaver Street

Waltham  Massachusetts  02453  U.S.A.
Phone: 781-891-3745 Fax: 781-891-3796

Adnexus is a Bristol-Myers Squibb R&D Company focused on the discovery and development of a new class of targeted biologics called Adnectins™. Targeted biologics are one of the most exciting and fastest growing areas of therapeutic medicine. These drugs specifically attack a disease target underlying important medical conditions. Until recently, there have been only two classes of targeted biologics: antibodies and soluble receptors. Adnexus is advancing an entirely new class of novel and proprietary targeted biologics. Adnectins are inherently easy to work with and they may offer important advantages over existing antibody and small molecule approaches.

Adnexus was formed in 2002 and remained a venture-financed biotech company until October 2007, when it was acquired by Bristol-Myers Squibb Company (BMS). This acquisition has further accelerated Adnexus' growth and better enabled it to lead the discovery and development of a new class of targeted biologics. With the experience and track record of BMS, Adnexus continues the clinical development of its first Adnectin product, CT-322, and is advancing multiple other Adnectin therapeutics in its pipeline.

Adnexus provides competitive compensation, excellent benefits, an outstanding work environment and career development opportunities. If you join us at Adnexus, you will discover a fun work environment that fosters your pursuit of excellence! Visit the Careers section of the Adnexus website at to get more information about our work environment, benefits and wellness programs.

Key Statistics

Ownership: Private

Web Site: Adnexus, A Bristol-Myers Squibb R&D Company


Company News
U.S. Approves Bristol-Myers Squibb (BMY)'s $430 Million Purchase of Adnexus Therapeutics 10/12/2007 10:47:47 AM
Bristol-Myers Squibb (BMY) (Jobs) to Buy Partner Adnexus Therapeutics for $430 Million 9/24/2007 7:23:38 AM
Adnexus Therapeutics Announces Additional Phase I and Preclinical Data on CT-322 at 6th International Congress on Targeted Therapies in Cancer 8/27/2007 10:19:16 AM
Adnexus Therapeutics Files for $86 Million IPO 8/21/2007 3:52:54 PM
Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors 8/21/2007 10:51:18 AM
Adnexus Therapeutics to Present Data on Adnectin Product Candidate, CT-322, at Gordon Research Conference 8/20/2007 12:15:03 PM
Adnexus Therapeutics Raises $15.5 Million in Series C Funding 8/9/2007 7:35:07 AM
Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer 7/11/2007 11:56:37 AM
Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research on Clinical Product Candidate, CT-322 4/17/2007 5:00:35 PM
Adnexus Therapeutics Announces Presentation Of Interim Phase I Results For CT-322, First Adnectin Therapeutic In Humans 2/2/2007 11:53:37 AM